课题基金 / 基金详情

DNA TOPOISOMERASES AS TARGET OF ACTION OF ANTICANCER DRUGS

DNA TOPOISOMERASES AS TARGET OF ACTION OF ANTICANCER DRUGS
DNA拓扑异构酶作为抗癌药物的作用靶点
批准号:
2463710
负责人:
Y POMMIER
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至

项目摘要

项目成果

Y POMMIER的其他基金

相似基金

相关文献

中文摘要
翻译
DNA拓扑异构酶I和II(top1和top2)是 癌症化疗。TOPO-异构酶毒物通过稳定 可被检测为与蛋白质相关的酶联DNA断裂 药物处理细胞中的DNA断裂(可切割的复合体)。然而, 拓扑异构酶在正常细胞和癌细胞中都存在,而且 肿瘤细胞药物选择性的机制(S)仍然很差(S) 明白了。这个项目的目标是阐明抗肿瘤 拓扑异构酶毒物的作用机制及其对肿瘤的选择性 细胞。癌细胞中不同的次要靶点可能是 与拓扑异构酶抑制剂联合用于药物开发 或其他DNA损伤剂。 我们研究了人类结肠癌和卵巢癌细胞系 NCI抗癌药物筛选以确定最佳参数 与细胞毒性相关,可用于临床预测 并监测对拓扑异构酶抑制剂的反应。Top1蛋白 不同细胞系之间的水平似乎具有可比性,因此不能预测, 而Top1可裂解的复合体与细胞毒性的相关性更好。 然而,可切割的复合体并不总是具有预测性。使用单元格 具有类似的可切割复合体的线,我们演示了 G2检查点和复制子修复的重要性,从 这些可切割的络合物具有细胞毒性。我们已经证明了 P53的存在提供了对抗喜树碱的生存优势 细胞毒性。这可能有助于喜树碱的选择性。 对于带有p53突变的癌细胞。 我们和其他人提出,细胞凋亡是癌症的一个关键反应 细胞对化疗药物的敏感性,特别是在暴露于白血病细胞中 拓扑异构酶抑制剂。我们已经证明,HL60细胞迅速 上调和下调细胞周期蛋白B/cdc2激酶活性 在DNA损伤后发生细胞凋亡。我们还建立了一个体外培养系统 无细胞系统研究细胞凋亡的生化途径。它 人类白血病HL60细胞似乎诱导了一系列的蛋白水解酶 包括ICE/CED3和丝氨酸蛋白酶对DNA损伤的反应 喜树碱治疗后,蛋白酶(S)被激活(S) 原核原核酸酶(S)。旨在触发 或抑制细胞凋亡可能提供新的治疗策略和 帮助减少药物副作用。
英文摘要
DNA topoisomerase I and II (top1 and top2) are primary targets for cancer chemotherapy. Topo-isomerase poisons act by stabilizing enzyme-linked DNA breaks which can be detected as protein-associated DNA breaks in drug-treated cells (cleavable complexes). However, topoisomerases exist both in normal and cancer cells, and the mechanism(s) of drug selectivity for cancer cells remain(s) poorly understood. The goal of this project is to elucidate the antitumor mechanisms of topoisomerase poisons, and their selectivity for cancer cells. Secondary targets which are different in cancer cells could be used for drug development in association with topoisomerase inhibitors or other DNA damaging agents. We have studied the human colon and ovarian cancer cell lines from the NCI Anticancer Drug Screen to identify the parameters that are best correlated with cytotoxicity and could be used in the clinic to predict and monitor the response to topoisomerase inhibitors. Top1 protein levels appear comparable among cell lines and thus are not predictive, while top1 cleavable complexes are better correlated with cytotoxicity. Cleavable complexes are, however, not always predictive . Using cells lines with comparable cleavable complexes, we demonstrated the importance of the G2 checkpoint and replicon repair, downstream from the cleavable complexes for cytotoxicity. We have shown that the presence of p53 provides a survival advantage against camptothecin cytotoxicity. This may contribute to the selectivity of camptothecins for cancer cells with p53 mutations. We and others have proposed that apoptosis is a key response of cancer cells to chemotherapeutic agents, especially in leukemia cells exposed to topoisomerase inhibitors. We have shown that HL60 cells rapidly upregulate and downregulate cyclin B/cdc2 kinase activity before undergoing apoptosis after DNA damage. We have also set up an in vitro cell-free system to study the biochemical pathways of apoptosis. It appears that human leukemia HL60 cells induce a protease cascade including both ICE/CED3 and serine proteases in response to DNA damage following camptothecin treatment and that the protease(s) activate(s) preexisting nuclear pronuclease(s). New approaches aimed at triggering or suppressing apoptosis may provide new therapeutic strategies and help reduce drug side effects.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PROTEIN-ASSOCIATED DNA BREAKS AS INDICATOR OF TOPOISOMERASE INHIBITION
  • 批准号:
    3916548
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    --
  • 负责人:
    Y POMMIER
  • 依托单位:
TOPOISOMERASE II AS TARGET OF ACTION OF ANTICANCER DRUG
  • 批准号:
    3939497
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    --
  • 负责人:
    Y POMMIER
  • 依托单位:
PHARMACOLOGY OF THE HIV VIRAL DNA
  • 批准号:
    3838171
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    --
  • 负责人:
    Y POMMIER
  • 依托单位:
PROTEIN-ASSOCIATED DNA BREAKS AS INDICATOR OF TOPOISOMERASE INHIBITION
  • 批准号:
    3752315
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    --
  • 负责人:
    Y POMMIER
  • 依托单位:
海外基金